F011 DataDerm: The First Decade and Goals for the Next
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
DataDerm includes ≥53 million patient encounters. Registry data can advance diagnosis and treatment of numerous conditions, guiding standards in clinical practice and research. Participants will describe DataDerm’s facilitation of registry-based research for common and rare skin diseases and associated treatment patterns. Speakers, including experts from DataDerm’s data partner, OM1, will demonstrate how to utilize registry data to improve patient care and drive clinical trial enrollment. With a range of patients and practices, DataDerm data reflects real world conditions and treatments, facilitating care patterns in dermatology. Longitudinal analyses of disease progression and treatment from registry data will be presented.
LEARNING OBJECTIVES
Demonstrate ideal ways to leverage registry data to advance the science of dermatology.
Describe discoveries in treatment patterns, disease responses, and co-morbidities in inflammatory skin disease.
Examine how DataDerm can be used to advocate for the specialty, identify gaps in care, and benefit practices of all types.
SCHEDULE
5:00 PM
DataDerm: A look back on the first 10 years
Marta Jane Van Beek, MD, MPH, FAAD
5:15 PM
Real World Data: Contact Dermatitis and Patch Testing
Margo Reeder, MD, FAAD
5:35 PM
Disease patterns and response to treatment
Joseph Zabinski, PhD
5:55 PM
Rosacea and cardiovascular risk
Benjamin Ungar, MD, FAAD
6:15 PM
The Power and Promise of Patient Reported Outcomes
Robert Swerlick, MD, FAAD
6:35 PM
The Future of DataDerm: How it Can Benefit Your Practice
Steven Daniel Daveluy, MD, FAAD
6:55 PM
Q&A
SPEAKERS
Steven Daniel Daveluy, MD, FAAD
Margo Reeder, MD, FAAD
Robert Swerlick, MD, FAAD
Benjamin Ungar, MD, FAAD
Marta Jane Van Beek, MD, MPH, FAAD
Joseph Zabinski, PhD
HANDOUTS
SPEAKER DISCLOSURES
Steven Daniel Daveluy, MD, FAAD
AbbVie – Speaker(Honoraria); MoonLake Immunotherapeutics – Investigator(Grants/Research Funding); Novartis – Speaker(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding); Sanofi – Investigator(Grants/Research Funding); UCB – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Honoraria);
Margo Reeder, MD, FAAD
American Contact Dermatitis Society – Employee(Salary); National Eczema Association – Consultant (1099 relationship)(Honoraria); UpToDate, Inc – Other(Fees);
Robert Swerlick, MD, FAAD
No financial relationships exist with ineligible companies.
Benjamin Ungar, MD, FAAD
Arcutis Biotherapeutics – Advisory Board(Honoraria); Bristol-Myers Squibb – Advisory Board(Honoraria); Castle Biosciences – Advisory Board(Honoraria); Fresenius Kabi – Advisory Board(Honoraria); Galderma – Advisory Board(Honoraria); Incyte Corporation – Investigator(Grants/Research Funding); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Primus Pharmaceuticals – Advisory Board(Honoraria); RAPT Therapeutics – Investigator(Grants/Research Funding); Sanofi – Advisory Board(Honoraria); Target-Derm – Advisory Board(Honoraria); UCB – Advisory Board(Honoraria);
Marta Jane Van Beek, MD, MPH, FAAD
No financial relationships exist with ineligible companies.
Joseph Zabinski, PhD
No financial relationships exist with ineligible companies.